Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Professor Lionel Tarassenko, CBE, Head of Engineering at the University of Oxford and Fellow of the Royal Academy of Engineering and the Academy of Medical Sciences, has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
As the worlds of science and technology come together, the 2015 Astellas Innovation Debate, organised and funded by Astellas, will discuss recent breakthroughs in genetic medicine and smart technology, and what they mean for our health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7432051-lionel-tarassenko-astellas-debate/
George Freeman MP, the Minister for Life Sciences, will give the keynote address at the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time.
George Freeman’s keynote address will outline the Government’s aim to develop, assess and adopt new drugs, devices and diagnostics as we move towards 21st century, personalised healthcare.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423951-george-freeman-astellas-debate/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Bright Starts™ introduces a fun new metric, the Baby Laugh Index™, in tandem with the launch of three new toys designed to inspire laughter. The inspirations for the focus on laughter are the three new baby toys from the Bright Starts Having a Ball™ collection: 3-in-1 Step ’N; Ride Lion™, Hide ’N Spin Monkey™ and Jungle Fun Ball Climber™. Teaming up with Gina Mireault, Ph.D. professor of psychology and counseling behavior sciences at Johnson State College and researcher of humor and emotional development in children, Bright Starts seeks to emphasize the importance of laughter in infant development.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7251151-bright-starts-tm-introduces-fun-new-baby-laugh-index/
Strand Life Sciences (Strand) announced today the version 2.0 release of its popular next-generation sequencing (NGS) data analysis and visualization platform, Avadis NGS, under a new name: Strand NGS. Strand NGS is built on the same award winning platform as Strand and Agilent Technologies’ GeneSpring®.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400564-Avadis-NGS-becomes-Strand-NGS
The American Transaction Processors Coalition (ATPC) formally launched today with a panel discussion in front of 400 industry employees, chamber of commerce executives, university leadership and elected officials from Congress, the Georgia General Assembly and local governments across metro Atlanta.
More than 40,000 employees work directly for 70-plus Georgia-based transaction processing companies within an area known as Transaction Alley. These companies generated more than $30 billion last year, far exceeding other well-known Georgia industries like life sciences at $17 billion or film at $3 billion. Transaction Alley revenues equal that of the entire U.S. movie industry, and is dominated by Atlanta, just as Los Angeles dominates films.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7081851-american-transaction-processors-coalition-launches-georgia-town-hall
People want to know—how do elite athletes prepare for their next fight, match, or race? It’s no surprise that athletes dedicate their lives to improving in their chosen sport, and many of them keep the same secret about how they maintain their craft at an elite level. But their secret is now out. It’s USANA Health Sciences.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7143551-usana-health-sciences-best-kept-secret-of-elite-athletes
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to maintain, ScienceCloud improves operational excellence in globally networked research, significantly reducing IT cost and effort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65595-sciencecloud-software-by-accelrys-advances-collaborative-drug-discovery
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries. The QUMAS acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document and process management compliance solutions. Proven quality management solutions supported by robust content and business process management capabilities provided by QUMAS advance Accelrys’ ability to help customers better manage the scientific innovation lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62188-accelrys-acquires-compliance-and-quality-management-leader-qumas
Cette année encore, la Fondation L’Oréal avec le soutien de L’Oréal France, la Commission française pour l’UNESCO et l’Académie des sciences a récompensé 25 jeunes doctorantes en sciences pour l’excellence de leurs travaux et le potentiel de leurs recherches, réaffirmant ainsi son engagement pour soutenir la promotion des femmes dans la science.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63475-loreal-unesco-women-science-awards
